


MONITORING AND EVALUATION FRAMEWORK FOR **HBV** AND **HCV** ELIMINATION

10 CORE INDICATORS: GLOBAL AND NATIONAL LEVELS



¹ In the case of testing of the mother followed by immunoprophylaxis, "newborns benefiting from other interventions to prevent mother-to-child transmission of HBV" would include children born to HBsAg-negative mothers and children born to HBsAg-positive mothers and who received immunoprophylaxis. Children born to mothers who were not tested and children born to HBsAg-positive mothers and who did not receive immunoprophylaxis would be excluded.
C: Core indicators.
HCC: Hepatocellular carcinoma.

27 ADDITIONAL INDICATORS: NATIONAL OR LOCAL LEVELS

10 NEW HEPATITIS INDICATORS

- A.1 Hepatitis D coinfection among people with **HBV**
- A.2 Experience with discrimination
- A.3 Availability of essential medicines and commodities
- A.4 National system for viral hepatitis surveillance
- A.5 **HBV** testing
- A.6 **HCV** testing
- A.7 **HCV** genotyping
- A.8 **HBV** and **HCV** care coverage
- A.9 Equitable access to hepatitis treatment
- A.10 Documentation of treatment outcome

17 EXISTING INDICATORS

- A.11 Estimated size of key populations (HIV)
- A.12 Key populations discrimination (HIV)
- A.13 Hepatitis coinfections among persons with HIV
- A.14 Condom use in key populations (HIV)
- A.15 National provision of a birth dose of **HBV** vaccine
- A.16 **HBV** vaccination among health-care workers
- A.17 Facility-level blood safety
- A.18 Blood screening coverage
- A.19 National policy for infection control programmes
- A.20 Supply of needles-syringes
- A.21 Procurement of reuse prevention devices
- A.22 Reuse of injection equipment
- A.23 Needle-stick injuries among health-care workers
- A.24 Opioid substitution therapy (OST) coverage
- A.25 Retention in OST
- A.26 Incidence of cancer, by cancer type
- A.27 Alcohol consumption per capita (age 15+ years)

A: Additional indicators.